GLP1R and metabolic dysfunction-associated steatohepatitis: Additionally, ongoing clinical trials of weekly GLP-1 RAs in NAFLD will provide further clarity on the safety and efficacy of this treatment, potentially solidifying the position of GLP-1 RAs in the clinical management of NAFLD/NASH.